No abstract available.
Peptic Ulcer Perforation* ; Peptic Ulcer*

No abstract available.
Appendicitis* ; Child* ; Humans

No abstract available.
Humans

Peroxisome proliferator-activated receptor-gamma (PPARgamma) has been implicated in the growth inhibition of a number of cancer cells. In the present study, we investigated the antitumor effect of the PPARgamma agonist rosiglitazone in U87MG human glioma cells. Rosiglitazone treatment in vitro reduced cell proliferation without induction of cell death in a dose- and time-dependent manner. Rosiglitazone decreased cell migration and mRNA level of MMP-9. Rosiglitazone treatment also induced marked changes in glioma cell morphology. Oral administration of rosiglitazone in animals with subcutaneous U87MG glioma cells reduced tumor volume. Subsequent tumor tissue analysis showed that rosiglitazone decreased the number of PCNA-positive staining cells and MMP-9 expression and induced apoptosis of tumor cells. These data suggest that rosiglitazone exerts antineoplastic effect in U87MG cells and may serve as potential therapeutic agent for malignant human gliomas.
Administration, Oral ; Animals ; Apoptosis ; Cell Death ; Cell Movement ; Cell Proliferation ; Glioma ; Humans ; Peroxisomes ; PPAR gamma ; RNA, Messenger ; Thiazolidinediones ; Tumor Burden

No abstract available.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

Malignant tumors of the small bowel are uncommon by comparison with those in other parts of the gastrointestinal tract. Adenocarcinomas account for about half of the malignant tumors of the small intestine, which account for 1% to 2% of the gastrointestinal neoplasma. Small-bowel tumors are often asymptomatic and without clinical significance, and later became symptomatic and are eventually fatal. Patient's with regional enteritis, especially those who have had segments of the intestine surgically by passed, have an increased incidence of small-bowel cancer. The author experienced a case of an adenocarcinoma at the jejunostomy site (Braun anastomosis) which was treated by using a B II type subtotal gastrectomy for stomach cancer. That case of a jejunostomy site adenocarcinoma is reported and the literature on small-bowel malignancy is reviewed.
Adenocarcinoma* ; Crohn Disease ; Gastrectomy ; Gastrointestinal Tract ; Incidence ; Intestine, Small ; Intestines ; Jejunostomy ; Stomach Neoplasms

To evaluate characteristic CT findings of orbital pseudotumor and to define differentialpoints from other pathology, the authors retrospectively reviewed CT of 19 patients who were prooen to have orbital pseudotumor by clinical course and, in some cases, biopsy. A variety of CT findings including extraocular muscle thickening(11 cases), streaky infiltration of retroorbital fat(11 cases), mass formation(10 cases), optic nerve thickening (6 cases), conjunctival thickening (5 cases), scleral thickening(4cases), enlarged lacrimal gland(4 cases) and destruction of orbital bone (2 cases) were observed. Thickening of the anterior portion and irregular margin were characteristic findings of extraocular muscle and optic nerve lesions. Mass formation predominantly occurs in the anterior portion of the orbit. In most cases more than two orbital structures are involved by lesion.
Biopsy ; Humans ; Optic Nerve ; Orbit* ; Orbital Pseudotumor* ; Pathology ; Retrospective Studies

OBJECTIVE: Microvascular decompression(MVD) is an effective technique for the patients who have trigeminal neuralgia(TN) and hemifacial spasm(HS). But, the failed MVD cases have been reported in long term follow-up studies. We introduce our unique operative technique in MVD and analyze the effect of MVD through our modified operative technique, offending vessels in operative field, operative complications, and failed cases. PATIENTS AND METHODS: A series of 52 patients with intractable TN(32 cases) or HS(20 cases) were treated by MVD. Other 7 cases of TN were excluded because they were proved to have TNs secondary to other pathologies, such as nasopharyngeal carcionoma, trigeminal schwannoma, epidermoid tumors, postherpetic neuralgia. The follow-up time was from 3 months to 4 years. RESULT: All 52 patients were treated by retromastoid suboccipital approach. 28 patients of TN were treated with MVD only, and the other 4 patients, were treated with selective sensory root squeezing(1 case), partial sensory rhizotomy(PSR)(2 cases), and PSR with MVD(1 case). Among 20 patients of HS were treated with MVD, 3 patients were not relieved after first operation but were free of spasm after reoperation within 1 week. The degree of nerve root compression was classified as compression and contact and the final outcome compared each other. We used our uniquely designed horseshoe-shaped teflon ring to decompress the vessel from the nerve. In TN, the most common offending vessel was superior cerebellar artery(59.4%) and the final outcomes were as follows: excellent, 87.5%(28 cases): good, 3.1%(1 case): poor, 9.4%(3 cases). In HS, the most common offending vessel was anterior inferior cerebellar artery(55%) and the final outcomes were as follows: excellent, 85%(17 cases): good, 5%(1 case): poor, 10%(2 cases). CONCLUSION: In compressed group, the cure rate was 100%. However, in contact group the cure rate were 81.3% in TN and 75% in HS. RESULT: From the review of the literatures in failed MVD, the etiologies most commonly reported were inadequate decompression, new vessel compression, adhesion and lysis of prosthesis. Our specially designed horseshoe-shaped teflon ring has some advantages to prevent recurrence of symptom by dislodging or slippage of prosthesis or recompression by other vessels. The overall result of our unique MVD was excellent in patients with TN(87.5%) and HS(85%).
Decompression ; Follow-Up Studies ; Hemifacial Spasm* ; Humans ; Microvascular Decompression Surgery* ; Neuralgia, Postherpetic ; Neurilemmoma ; Pathology ; Polytetrafluoroethylene ; Prostheses and Implants ; Radiculopathy ; Recurrence ; Reoperation ; Spasm ; Trigeminal Neuralgia*

No abstract available.
Colorectal Neoplasms, Hereditary Nonpolyposis*

Nimodipine, a potent, central active, calcium channel blocker, is known to relieve vasospasm, increase cerebral blood flow(CBF) and affect positively on clinical outcome in patients with subarachnoid hemorrhage. Experimentally, the potent effects on both vascular dilatation and increasing CBF were proven. However, there are still controversies and many debates at present about the actual clinical effects of nimodipine on subarachnoid hemorrhage. To evaluate the clinical effectiveness of nimodipine on aneurysmal subarachnoid hemorrhage in our series, we analyzed 122 consecutive patients with ruptured aneurysms who underwent operations between October, 1993 and June, 1995. These patients were grouped as follow: Group I consisted of 63 cases(52%) in which the patients were treated with nimodipine and Group II consisted of 59 cases(48%) in which the patients were treated conventionally. Administration of nimodipine was started immediately after the radiological diagnosis of ruptured aneurysm. The dose of nimodipine was 0.5microg/kg/min via continuous intravenous infusion for 7 to 10 days after the subarachnoid hemorrhage. After a course of intravenous treatment, oral administration of nimodipine was then continued for up to 21 days after subarachnoid hemorrhage in a dose of 60mg every four hours. We analyzed two groups based on patient's age, sex, aneurysmal location and size, timing of surgery, presence of hypertension, Hunt-Hess grade, presence of vasospasm on preoperative angiography and Fisher's CT classification. We also analyzed the incidence of delayed ischemic deficits(DID) and outcome(GOS) in each group. There were no significant differences in any of these parameters between nimodipine-treated group and the control group(p>0.05) and also, no significant differences in the distribution of DID or outcome between two groups (p>0.05). Based on these results, we conclude that nimodipine does not provide any significant beneficial effects on the prevention of DID and outcome in the patients with aneurysmal subarachnoid hemorrhage.
Administration, Oral ; Aneurysm* ; Aneurysm, Ruptured ; Angiography ; Calcium Channels ; Classification ; Diagnosis ; Dilatation ; Humans ; Hypertension ; Incidence ; Infusions, Intravenous ; Nimodipine* ; Subarachnoid Hemorrhage*